{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination induces a strong local type I interferon response in tumors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "The report summarizes normalized scores, but does not specify timing, assay details, or variability across models in this excerpt."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination broadens tumor antigen presentation, including an expanded MHC-I peptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "The intervention increases PD-L1 pathway activity in tumor tissue, supporting combination with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "An increase in PD-L1 expression can have multiple biological interpretations, and the excerpt does not provide effect sizes across all tumor models."
    },
    {
      "claim_id": "C04",
      "claim": "Combination therapy improves tumor control in mice and is consistent with improved survival in a retrospective vaccinated human subgroup receiving ICI.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients."
    },
    {
      "claim_id": "C05",
      "claim": "The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "These results are described at a summary level here, and the excerpt does not specify which tumor models or endpoints were used for the IFNAR1 perturbation." 
    }
  ]
}
